{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:31:07Z","timestamp":1777498267512,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Department of Health Research","award":["No: V.25011\/450-HRD\/2016-HR"],"award-info":[{"award-number":["No: V.25011\/450-HRD\/2016-HR"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11010-021-04134-0","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T13:02:59Z","timestamp":1616763779000},"page":"2975-2987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Design and development of novel inhibitors of aldo-ketoreductase 1C1 as potential lead molecules in treatment of breast cancer"],"prefix":"10.1007","volume":"476","author":[{"given":"Priyanka","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Imtaiyaz","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-8471","authenticated-orcid":false,"given":"Indrakant K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"issue":"2015","key":"4134_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(2015):E359-386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"key":"4134_CR2","doi-asserted-by":"crossref","unstructured":"WHO World Cancer Report 2008, Anticancer Res. 29 (2009) 29.11.10a","DOI":"10.1002\/med.20137"},{"key":"4134_CR3","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1101\/gad.9.18.2266","volume":"9","author":"JP Lydon","year":"1995","unstructured":"Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, Shyamala G, Conneely OM, O\u2019Malley BW (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9:2266\u20132278. https:\/\/doi.org\/10.1101\/gad.9.18.2266","journal-title":"Genes Dev"},{"key":"4134_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1210\/edrv.18.4.0308","volume":"18","author":"JD Graham","year":"1997","unstructured":"Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocr Rev 18:502\u2013519. https:\/\/doi.org\/10.1210\/edrv.18.4.0308","journal-title":"Endocr Rev"},{"key":"4134_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1210\/me.2009-0016","volume":"23","author":"CR Mendelson","year":"2009","unstructured":"Mendelson CR (2009) Minireview: fetal-maternal hormonal signaling in pregnancy and labor. Mol Endocrinol 23:947\u2013954. https:\/\/doi.org\/10.1210\/me.2009-0016","journal-title":"Mol Endocrinol"},{"key":"4134_CR6","doi-asserted-by":"publisher","first-page":"E719","DOI":"10.1210\/jc.2011-3251","volume":"97","author":"H Tan","year":"2012","unstructured":"Tan H, Yi L, Rote NS, Hurd WW, Mesiano S (2012) Progesterone receptor-A and -B have opposite effects on proinflammatory gene expression in human myometrial cells: implications for progesterone actions in human pregnancy and parturition. J Clin Endocrinol Metab 97:E719\u2013E730. https:\/\/doi.org\/10.1210\/jc.2011-3251","journal-title":"J Clin Endocrinol Metab"},{"key":"4134_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1067\/mob.2003.41","volume":"188","author":"EB da Fonseca","year":"2003","unstructured":"da Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M (2003) Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 188:419\u2013424. https:\/\/doi.org\/10.1067\/mob.2003.41","journal-title":"Am J Obstet Gynecol"},{"key":"4134_CR8","first-page":"60","volume":"4","author":"ER Norwitz","year":"2011","unstructured":"Norwitz ER, Caughey AB (2011) Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol 4:60\u201372","journal-title":"Rev Obstet Gynecol"},{"key":"4134_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/humupd\/5.4.365","volume":"5","author":"E Cicinelli","year":"1999","unstructured":"Cicinelli E, de Ziegler D (1999) Transvaginal progesterone: evidence for a new functional \u201cportal system\u201d flowing from the vagina to the uterus. Hum Reprod Update 5:365\u2013372. https:\/\/doi.org\/10.1093\/humupd\/5.4.365","journal-title":"Hum Reprod Update"},{"key":"4134_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s0015-0282(16)48670-x","volume":"44","author":"JA Rock","year":"1985","unstructured":"Rock JA, Wentz AC, Cole KA, Kimball AW, Zacur HA, Early SA, Jones GS (1985) Fetal malformations following progesterone therapy during pregnancy: a preliminary report. Fertil Steril 44:17\u201319. https:\/\/doi.org\/10.1016\/s0015-0282(16)48670-x","journal-title":"Fertil Steril"},{"key":"4134_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamaoncol.2015.0494","volume":"1","author":"RT Chlebowski","year":"2015","unstructured":"Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O\u2019Sullivan MJ, Adams-Campbell LL, Nassir R, Lessin LS, Prentice RL (2015) Breast cancer after use of estrogen plus progestin and estrogen alone. JAMA Oncol 1:296\u2013305. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0494","journal-title":"JAMA Oncol"},{"key":"4134_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.steroids.2013.10.012","volume":"79","author":"TL Ri\u017ener","year":"2014","unstructured":"Ri\u017ener TL, Penning TM (2014) Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids 79:49\u201363. https:\/\/doi.org\/10.1016\/j.steroids.2013.10.012","journal-title":"Steroids"},{"key":"4134_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1210\/me.2004-0302","volume":"19","author":"RP Piekorz","year":"2005","unstructured":"Piekorz RP, Gingras S, Hoffmeyer A, Ihle JN, Weinstein Y (2005) Regulation of progesterone levels during pregnancy and parturition by signal transducer and activator of transcription 5 and 20\u03b1-hydroxysteroid dehydrogenase. Mol Endocrinol 19:431\u2013440. https:\/\/doi.org\/10.1210\/me.2004-0302","journal-title":"Mol Endocrinol"},{"key":"4134_CR14","doi-asserted-by":"publisher","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-04-1608","volume":"64","author":"Q Ji","year":"2004","unstructured":"Ji Q, Aoyama C, Nien Y-D, Liu PI, Chen PK, Chang L, Stanczyk FZ, Stolz A (2004) Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res 64:7610\u20137617. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1608","journal-title":"Cancer Res"},{"key":"4134_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2407-4-27","volume":"4","author":"MJ Lewis","year":"2004","unstructured":"Lewis MJ, Wiebe JP, Heathcote JG (2004) Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4:27. https:\/\/doi.org\/10.1186\/1471-2407-4-27","journal-title":"BMC Cancer"},{"key":"4134_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0009-2797(02)00206-5","volume":"143\u2013144","author":"Y Higaki","year":"2003","unstructured":"Higaki Y, Usami N, Shintani S, Ishikura S, El-Kabbani O, Hara A (2003) Selective and potent inhibitors of human 20\u03b1-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact 143\u2013144:503\u2013513. https:\/\/doi.org\/10.1016\/S0009-2797(02)00206-5","journal-title":"Chem Biol Interact"},{"key":"4134_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.mce.2005.10.009","volume":"248","author":"TL Rizner","year":"2006","unstructured":"Rizner TL, Smuc T, Rupreht R, Sinkovec J, Penning TM (2006) AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 248:126\u2013135. https:\/\/doi.org\/10.1016\/j.mce.2005.10.009","journal-title":"Mol Cell Endocrinol"},{"key":"4134_CR18","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.1021\/jm3007867","volume":"55","author":"SMF Jamieson","year":"2012","unstructured":"Jamieson SMF, Brooke DG, Heinrich D, Atwell GJ, Silva S, Hamilton EJ, Turnbull AP, Rigoreau LJM, Trivier E, Soudy C, Samlal SS, Owen PJ, Schroeder E, Raynham T, Flanagan JU, Denny WA (2012) 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids: highly potent and selective inhibitors of the type 5 17-\u03b2-hydroxysteroid dehydrogenase AKR1C3. J Med Chem 55:7746\u20137758. https:\/\/doi.org\/10.1021\/jm3007867","journal-title":"J Med Chem"},{"key":"4134_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2174\/157340607782360399","volume":"3","author":"U Dhagat","year":"2007","unstructured":"Dhagat U, Carbone V, Chung RP-T, Matsunaga T, Endo S, Hara A, El-Kabbani O (2007) A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase. Med Chem 3:546\u2013550. https:\/\/doi.org\/10.2174\/157340607782360399","journal-title":"Med Chem"},{"key":"4134_CR20","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1016\/j.bmcl.2012.03.085","volume":"22","author":"M Chen","year":"2012","unstructured":"Chen M, Adeniji AO, Twenter BM, Winkler JD, Christianson DW, Penning TM (2012) Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. Bioorg Med Chem Lett 22:3492\u20133497. https:\/\/doi.org\/10.1016\/j.bmcl.2012.03.085","journal-title":"Bioorg Med Chem Lett"},{"key":"4134_CR21","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1021\/jm201547v","volume":"55","author":"AO Adeniji","year":"2012","unstructured":"Adeniji AO, Twenter BM, Byrns MC, Jin Y, Chen M, Winkler JD, Penning TM (2012) Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J Med Chem 55:2311\u20132323. https:\/\/doi.org\/10.1021\/jm201547v","journal-title":"J Med Chem"},{"key":"4134_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jsbmb.2010.10.006","volume":"125","author":"O El-Kabbani","year":"2011","unstructured":"El-Kabbani O, Dhagat U, Hara A (2011) Inhibitors of human 20\u03b1-hydroxysteroid dehydrogenase (AKR1C1). J Steroid Biochem Mol Biol 125:105\u2013111. https:\/\/doi.org\/10.1016\/j.jsbmb.2010.10.006","journal-title":"J Steroid Biochem Mol Biol"},{"key":"4134_CR23","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1016\/j.ejmech.2009.01.028","volume":"44","author":"B \u0160tefane","year":"2009","unstructured":"\u0160tefane B, Bro\u017ei\u010d P, Vehovc M, Ri\u017ener TL, Gobec S (2009) New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem 44:2563\u20132571. https:\/\/doi.org\/10.1016\/j.ejmech.2009.01.028","journal-title":"Eur J Med Chem"},{"key":"4134_CR24","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1016\/j.bmcl.2011.01.076","volume":"21","author":"O El-Kabbani","year":"2011","unstructured":"El-Kabbani O, Dhagat U, Soda M, Endo S, Matsunaga T, Hara A (2011) Probing the inhibitor selectivity pocket of human 20\u03b1-hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and site-directed mutagenesis. Bioorg Med Chem Lett 21:2564\u20132567. https:\/\/doi.org\/10.1016\/j.bmcl.2011.01.076","journal-title":"Bioorg Med Chem Lett"},{"key":"4134_CR25","doi-asserted-by":"publisher","first-page":"7417","DOI":"10.1021\/jm300841n","volume":"55","author":"P Bro\u017ei\u010d","year":"2012","unstructured":"Bro\u017ei\u010d P, Turk S, Adeniji AO, Konc J, Jane\u017ei\u010d D, Penning TM, Ri\u017ener TL, Gobec S (2012) Selective inhibitors of Aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library. J Med Chem 55:7417\u20137424. https:\/\/doi.org\/10.1021\/jm300841n","journal-title":"J Med Chem"},{"key":"4134_CR26","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1021\/jm8003575","volume":"51","author":"U Dhagat","year":"2008","unstructured":"Dhagat U, Endo S, Sumii R, Hara A, El-Kabbani O (2008) Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid. J Med Chem 51:4844\u20134848. https:\/\/doi.org\/10.1021\/jm8003575","journal-title":"J Med Chem"},{"key":"4134_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.abb.2008.08.014","volume":"479","author":"V Carbone","year":"2008","unstructured":"Carbone V, Chung R, Endo S, Hara A, El-Kabbani O (2008) Structure of aldehyde reductase in ternary complex with coenzyme and the potent 20\u03b1-hydroxysteroid dehydrogenase inhibitor 3,5-dichlorosalicylic acid: Implications for inhibitor binding and selectivity. Arch Biochem Biophys 479:82\u201387. https:\/\/doi.org\/10.1016\/j.abb.2008.08.014","journal-title":"Arch Biochem Biophys"},{"key":"4134_CR28","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1021\/jm9001633","volume":"52","author":"O El-Kabbani","year":"2009","unstructured":"El-Kabbani O, Scammells PJ, Gosling J, Dhagat U, Endo S, Matsunaga T, Soda M, Hara A (2009) Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1). J Med Chem 52:3259\u20133264. https:\/\/doi.org\/10.1021\/jm9001633","journal-title":"J Med Chem"},{"key":"4134_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1248\/bpb.25.441","volume":"25","author":"N Usami","year":"2002","unstructured":"Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A (2002) Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull 25:441\u2013445. https:\/\/doi.org\/10.1248\/bpb.25.441","journal-title":"Biol Pharm Bull"},{"key":"4134_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","volume":"15","author":"VE Kwitkowski","year":"2010","unstructured":"Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R (2010) FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15:428\u2013435. https:\/\/doi.org\/10.1634\/theoncologist.2009-0178","journal-title":"Oncologist"},{"key":"4134_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1021\/ml500394m","volume":"6","author":"K Okamoto","year":"2014","unstructured":"Okamoto K, Ikemori-Kawada M, Jestel A, von K\u00f6nig K, Funahashi Y, Matsushima T, Tsuruoka A, Inoue A, Matsui J (2014) Distinct binding mode of multikinase inhibitor Lenvatinib revealed by biochemical characterization. ACS Med Chem Lett 6:89\u201394. https:\/\/doi.org\/10.1021\/ml500394m","journal-title":"ACS Med Chem Lett"},{"key":"4134_CR32","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/50700987","volume":"5","author":"S-K Lin","year":"2000","unstructured":"Lin S-K (2000) Pharmacophore perception, development and use in drug design. Edited by Osman F. G\u00fcner. Molecules 5:987\u2013989. https:\/\/doi.org\/10.3390\/50700987","journal-title":"Edited by Osman F. G\u00fcner. Molecules"},{"key":"4134_CR33","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2174\/0929867013372481","volume":"8","author":"Y Kurogi","year":"2001","unstructured":"Kurogi Y, G\u00fcner OF (2001) Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr Med Chem 8:1035\u20131055. https:\/\/doi.org\/10.2174\/0929867013372481","journal-title":"Curr Med Chem"},{"key":"4134_CR34","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.ejmech.2010.01.016","volume":"45","author":"S Sakkiah","year":"2010","unstructured":"Sakkiah S, Thangapandian S, John S, Kwon YJ, Lee KW (2010) 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Eur J Med Chem 45:2132\u20132140. https:\/\/doi.org\/10.1016\/j.ejmech.2010.01.016","journal-title":"Eur J Med Chem"},{"key":"4134_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtice.2011.02.012","volume":"42","author":"M Chandrasekaran","year":"2011","unstructured":"Chandrasekaran M, Sakkiah S, Lee KW (2011) Combined ligand based pharmacophore modeling, virtual screening methods to identify critical chemical features of novel potential inhibitors for phosphodiesterase-5. J Taiwan Inst Chem Eng 42:709\u2013718. https:\/\/doi.org\/10.1016\/j.jtice.2011.02.012","journal-title":"J Taiwan Inst Chem Eng"},{"key":"4134_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01275","author":"BJ Neves","year":"2018","unstructured":"Neves BJ, Braga RC, Melo-Filho CC, Moreira-Filho JT, Muratov EN, Andrade CH (2018) QSAR-based virtual screening: advances and applications in drug discovery. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2018.01275","journal-title":"Front Pharmacol"},{"key":"4134_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.cbi.2015.09.006","volume":"240","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Zheng X, Zhang H, Zhai J, Zhang L, Li C, Zeng K, Chen Y, Li Q, Hu X (2015) In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact 240:310\u2013315. https:\/\/doi.org\/10.1016\/j.cbi.2015.09.006","journal-title":"Chem Biol Interact"},{"key":"4134_CR38","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/jcc.10306","volume":"24","author":"G Wu","year":"2003","unstructured":"Wu G, Robertson DH, Brooks CL, Vieth M (2003) Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 24:1549\u20131562. https:\/\/doi.org\/10.1002\/jcc.10306","journal-title":"J Comput Chem"},{"key":"4134_CR39","unstructured":"EZDetectTM Aldo-keto Reductase Activity Assay Kit (Colorimetric) | K847 | BioVision, Inc. (n.d.). https:\/\/www.biovision.com\/ezdetecttm-aldo-keto-reductase-activity-assay-kit-colorimetric.html. Accessed 14 May 2020"},{"key":"4134_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jtice.2012.01.004","volume":"43","author":"P Elumalai","year":"2012","unstructured":"Elumalai P, Liu H-L, Zhao J-H, Chen W, Lin DS, Chuang C-K, Tsai W-B, Ho Y (2012) Pharmacophore modeling, virtual screening and docking studies to identify novel HNMT inhibitors. J Taiwan Inst Chem Eng 43:493\u2013503. https:\/\/doi.org\/10.1016\/j.jtice.2012.01.004","journal-title":"J Taiwan Inst Chem Eng"},{"key":"4134_CR41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/jnci\/92.4.328","volume":"92","author":"RK Ross","year":"2000","unstructured":"Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328\u2013332. https:\/\/doi.org\/10.1093\/jnci\/92.4.328","journal-title":"J Natl Cancer Inst"},{"key":"4134_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/oxfordjournals.epirev.a036102","volume":"15","author":"MC Pike","year":"1993","unstructured":"Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15:17\u201335. https:\/\/doi.org\/10.1093\/oxfordjournals.epirev.a036102","journal-title":"Epidemiol Rev"},{"issue":"Suppl 2","key":"4134_CR43","doi-asserted-by":"publisher","first-page":"s141","DOI":"10.1590\/s0036-36342009000800003","volume":"51","author":"PL Porter","year":"2009","unstructured":"Porter PL (2009) Global trends in breast cancer incidence and mortality. Salud Publica Mex 51(Suppl 2):s141-146. https:\/\/doi.org\/10.1590\/s0036-36342009000800003","journal-title":"Salud Publica Mex"},{"key":"4134_CR44","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.7314\/apjcp.2013.14.9.5077","volume":"14","author":"GR Babu","year":"2013","unstructured":"Babu GR, Lakshmi SB, Thiyagarajan JA (2013) Epidemiological correlates of breast cancer in South India. Asian Pac J Cancer Prev 14:5077\u20135083. https:\/\/doi.org\/10.7314\/apjcp.2013.14.9.5077","journal-title":"Asian Pac J Cancer Prev"},{"key":"4134_CR45","first-page":"56","volume":"8","author":"I Ali","year":"2011","unstructured":"Ali I, Wani W, Saleem K, Correspondence (2011) Cancer scenario in India with future perspectives. Cancer Ther 8:56\u201370","journal-title":"Cancer Ther"},{"key":"4134_CR46","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/S0140-6736(05)67343-6","volume":"366","author":"K Srinath Reddy","year":"2005","unstructured":"Srinath Reddy K, Shah B, Varghese C, Ramadoss A (2005) Responding to the threat of chronic diseases in India. Lancet 366:1744\u20131749. https:\/\/doi.org\/10.1016\/S0140-6736(05)67343-6","journal-title":"Lancet"},{"key":"4134_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/0019-509X.112307","volume":"50","author":"SM Balasubramaniam","year":"2013","unstructured":"Balasubramaniam SM, Rotti SB, Vivekanandam S (2013) Risk factors of female breast carcinoma: a case control study at Puducherry. Indian J Cancer 50:65\u201370. https:\/\/doi.org\/10.4103\/0019-509X.112307","journal-title":"Indian J Cancer"},{"key":"4134_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/0971-5851.96961","volume":"33","author":"K Kaarthigeyan","year":"2012","unstructured":"Kaarthigeyan K (2012) Cervical cancer in India and HPV vaccination. Indian J Med Paediatr Oncol 33:7\u201312. https:\/\/doi.org\/10.4103\/0971-5851.96961","journal-title":"Indian J Med Paediatr Oncol"},{"key":"4134_CR49","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1210\/mend.13.6.0290","volume":"13","author":"CA Lange","year":"1999","unstructured":"Lange CA, Richer JK, Horwitz KB (1999) Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 13:829\u2013836. https:\/\/doi.org\/10.1210\/mend.13.6.0290","journal-title":"Mol Endocrinol"},{"key":"4134_CR50","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1210\/edrv-11-2-266","volume":"11","author":"CL Clarke","year":"1990","unstructured":"Clarke CL, Sutherland RL (1990) Progestin regulation of cellular proliferation. Endocr Rev 11:266\u2013301. https:\/\/doi.org\/10.1210\/edrv-11-2-266","journal-title":"Endocr Rev"},{"key":"4134_CR51","doi-asserted-by":"publisher","first-page":"11161","DOI":"10.1073\/pnas.96.20.11161","volume":"96","author":"H Ma","year":"1999","unstructured":"Ma H, Penning TM (1999) Conversion of mammalian 3\u03b1-hydroxysteroid dehydrogenase to 20\u03b1-hydroxysteroid dehydrogenase using loop chimeras: changing specificity from androgens to progestins. Proc Natl Acad Sci USA 96:11161\u201311166","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-021-04134-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-021-04134-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-021-04134-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T10:34:22Z","timestamp":1625654062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-021-04134-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4134"],"URL":"https:\/\/doi.org\/10.1007\/s11010-021-04134-0","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No competing interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}